MedTrace Logo

SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients

NCT04673383 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2024-03-27

No results posted yet for this study

Summary

SPL026 (N,N-dimethyltryptamine \[DMT\] fumarate) is a psychedelic tryptamine being developed as a therapy for patients with major depressive disorder (MDD).

Conditions

Interventions

DRUG

SPL026

Intravenous solution

DRUG

Placebo

SPL026-matched placebo

Sponsors & Collaborators

  • Small Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • David Erritzoe, MD · Imperial College London

  • Malcolm Boyce, MD · Hammersmith Medicines Research

  • Fabian Devlin, MD · MAC Clinical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-04
Primary Completion
2022-10-01
Completion
2022-12-22

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04673383 on ClinicalTrials.gov